← Back to Search

Other

SNV1521 for Advanced Cancer

Phase 1
Recruiting
Research Sponsored by Synnovation Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Advanced or metastatic solid tumor malignancy
ECOG Performance Status 0 or 1
Must not have
Significant gastrointestinal disease
Liver dysfunction
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from first dose through last dose (up to 13 months)
Awards & highlights

Summary

"This trial is testing a new medicine called SNV1521 for people with advanced cancers. The researchers are trying to see if the medicine is safe, well-tolerated, and effective in treating solid

Who is the study for?
This trial is for people with advanced solid tumors that are measurable, who have tried other treatments without success or can't tolerate them. Participants should be relatively active and mobile (ECOG status 0 or 1) and expected to live more than three months.
What is being tested?
The study is testing SNV1521, a new medication for advanced cancers. It aims to determine the safety, tolerability, and effectiveness of SNV1521 by exploring different doses to find the best balance between efficacy and safety.
What are the potential side effects?
While specific side effects of SNV1521 aren't listed here, common side effects from cancer drugs may include nausea, fatigue, skin reactions, blood count changes leading to increased infection risk or bleeding tendencies.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My cancer has spread beyond its original location.
Select...
I am fully active or restricted in physically strenuous activity but can do light work.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a serious stomach or intestine condition.
Select...
I have liver problems.
Select...
I have active cancer spread to my brain or its coverings.
Select...
I have had cancer other than my current diagnosis in the last 2 years.
Select...
I have HIV with a low CD4+ count or detectable virus.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from first dose through last dose (up to 13 months)
This trial's timeline: 3 weeks for screening, Varies for treatment, and from first dose through last dose (up to 13 months) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Safety of SNV1521
Tolerability of SNV1521

Trial Design

2Treatment groups
Experimental Treatment
Group I: Dose ExpansionExperimental Treatment1 Intervention
Group II: Dose EscalationExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Synnovation Therapeutics, Inc.Lead Sponsor
~51 spots leftby Dec 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top